1:1 Bonus Shares & 1:5 Stock Split: 15th October Record Date; Are You An Eligible Shareholder?

Vaishali Pharma, which was established in 1989, is among the pharmaceutical industry's fastest-growing companies worldwide. Its headquarters are in Mumbai, India's economic center. It also has an office in Vietnam. One of the largest selections of Active Pharmaceutical Ingredients (API) is provided by Vaishali Pharma. For more than five years, Vaishali Pharma has been offering high-performance surgical solutions and selling veterinary medicines.

Vaishali Pharma Record Date For Bonus Shares & Stock Split

"We wish to inform that the Company has fixed the "Record Date" as Tuesday, 15th October, 2024. The Company will Split its Equity Shares having nominal/face value of INR 10 each (Rupees Ten only), into 5 (Five) equity shares of INR 2 each (Rupee Two only) of the Shareholders holding shares as on Record Date i.e Tuesday, 15th October, 2024. Further the Bonus Shares will be issued to the Shareholders of the Company in the ratio of 1:1 i.e., 1 (One) new fully paid-up Equity Share of ₹ 2/- (Rupees Two Only) each for every 1 (One) existing fully paid-up Equity Share of ₹ 2/- (Rupees Two Only) each held by the eligible Shareholders of the Company as on the Record Date i.e Tuesday, 15th October, 2024. Please note that shareholders who are allotted equity shares pursuant to the conversion of warrants, and whose listing application is pending with the NSE, will also be eligible for the bonus shares," said Vaishali Pharma in a stock exchange filing.

Vaishali Pharma Financials

Vaishali Pharma's net profit increased to Rs 1.70 crore in the quarter that ended in June 2024 from Rs 1.59 crore in the quarter that ended in June 2023, a 6.92% growth. Sales for the quarter ended June 2024 climbed 34.72% to Rs 18.08 crore from Rs 13.42 crore in the corresponding quarter ending June 2023.

Vaishali Pharma Share Price Target

"Vaishali Pharma stock price is bullish on the Daily charts with strong support at 190. A Daily close above resistance of 198 could lead to a target of 210 in the near term," recommended A R Ramachandran, Independent Research Analyst.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.